赛升药业：预计2025年净利润1377.37万元至2000万元

Core Viewpoint - The company expects to achieve a positive net profit in 2025, marking a turnaround from previous losses, with a projected net profit attributable to shareholders ranging from 13.77 million to 20 million yuan, compared to a loss of 68.85 million yuan in the same period last year [1] Financial Performance - The anticipated net profit for 2025 is between 13.77 million and 20 million yuan, indicating a significant improvement from the previous year's loss of 68.85 million yuan [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -28.69 million and -23.47 million yuan, reflecting a decline of 299.58% to 343.93% compared to the previous year [1] Investment Gains - The increase in financial asset fair value changes and investment income from joint ventures is the primary reason for the expected improvement in net profit [1] - The company’s investments in financial assets, mainly in biopharmaceuticals, medical devices, and health-related investment funds, contributed approximately 19 million yuan in fair value gains and joint venture income, representing an increase of about 110% [1]